Lenvatinib plus pembrolizumab for advanced or recurrent endometrial cancer: a retrospective multi-institutional survey in the Kinki district of Japan - PubMed
4 days ago
- #Pembrolizumab
- #Endometrial cancer
- #Lenvatinib
- Lenvatinib plus pembrolizumab therapy is a new treatment option for advanced or recurrent endometrial cancer.
- A retrospective study of 161 patients in the Kinki district of Japan showed median overall survival (OS) of 27 months and median progression-free survival (PFS) of 9 months.
- Patients with proficient mismatch repair (pMMR) had median OS of 21 months and median PFS of 8 months.
- Carcinosarcoma patients (n=14) had median OS of 20 months and median PFS of 9 months.
- Univariate analysis linked histological subtype and MMR status to PFS, and histological subtype, MMR status, and platinum-free interval to OS.
- Multivariate analysis identified age and histological subtype as significant for PFS, and histological subtype, MMR status, and platinum-free interval for OS.
- The combination therapy was more effective for patients with longer platinum-free interval (>6 months), endometrioid carcinoma, or deficient MMR.
- Authors disclosed financial interests from MSD K.K. and Eisai Co., Ltd.